VANCOUVER, May 10, 2016 /CNW/ - Veritas Pharma Inc. ("VRT" or the "Company") (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) is pleased to announce that the first order of two popular cannabis strains has been placed with Whistler Medical Marijuana Corporation.
Veritas Pharma CEO, Dr. Lui Franciosi stated, "This will be the first order of many with Whistler. The Cannevert scientists are eager to start screening 'TRAIN WRECK' and 'NORTHERN TONIC' brands of cannabis given their known cannabinoid characteristics." Cannevert has the necessary chemical and pharmacological assays in place to immediately assess them. Orders of other diverse strains will be placed on a weekly basis.
Whistler Medical Marijuana Corporation (WMMC) is one of only 19 cultivation and sale licenses for dried marijuana and one of only 15 licensed producers of fresh marijuana and cannabis oil in Canada. It is also Canada's first certified organic medical marijuana producer (Fraser Valley Organic Producers Association). It has an expert team with over 20 years of growing experience in high-tech organic growing systems.
More information about WMMC can be found at www.whistlermedicalmarijuana.com
About VERITAS Pharma Inc.
Veritas Pharma Inc. is an early stage pharmaceutical company developing innovative medicinal cannabis cultivars for specific disease conditions such as chronic pain, emesis (nausea/vomiting), and epilepsy. Using a 'lean and mean' approach to product development, the company aims to select candidate cultivars using classical pharmacology techniques and then immediately evaluate them in the clinic to maximize both product value and shareholder return. Veritas's scientists are an inter-disciplinary team that consists of chemists, pharmacologists, anesthetists, and clinical pharmacologists. Their focus is to use their knowledge to streamline the development of cannabis based treatments to capture considerable market share.
On behalf of the Board of Directors Veritas Pharma Inc.
"Dr. Lui Franciosi"
Dr. Lui Franciosi
Chief Executive Officer
The CSE has not reviewed, nor approved or disapproved the content of this press release.
SOURCE Veritas Pharma Inc.
For further information: Investor and Public Relations Contact: Veritas Pharma Inc., Sam Eskandari, Telephone: +1.416.918.6785, Email: firstname.lastname@example.org, Website: www.veritaspharmainc.com